<?xml version="1.0" encoding="UTF-8"?>
<ref id="B38-marinedrugs-17-00567">
 <label>38.</label>
 <element-citation publication-type="journal">
  <person-group person-group-type="author">
   <name>
    <surname>Alexandre</surname>
    <given-names>K.B.</given-names>
   </name>
   <name>
    <surname>Gray</surname>
    <given-names>E.S.</given-names>
   </name>
   <name>
    <surname>Mufhandu</surname>
    <given-names>H.</given-names>
   </name>
   <name>
    <surname>McMahon</surname>
    <given-names>J.B.</given-names>
   </name>
   <name>
    <surname>Chakauya</surname>
    <given-names>E.</given-names>
   </name>
   <name>
    <surname>Oâ€™Keefe</surname>
    <given-names>B.R.</given-names>
   </name>
   <name>
    <surname>Chikwamba</surname>
    <given-names>R.</given-names>
   </name>
   <name>
    <surname>Morris</surname>
    <given-names>L.</given-names>
   </name>
  </person-group>
  <article-title>The lectins griffithsin, cyanovirin-n and scytovirin inhibit HIV-1 binding to the DC-SIGN receptor and transfer to CD4(+) cells</article-title>
  <source>Virology</source>
  <year>2012</year>
  <volume>423</volume>
  <fpage>175</fpage>
  <lpage>186</lpage>
  <pub-id pub-id-type="doi">10.1016/j.virol.2011.12.001</pub-id>
  <pub-id pub-id-type="pmid">22209231</pub-id>
 </element-citation>
</ref>
